ERAS · Erasca, Inc. · Stock research

Current Thesis

• The leg an investor is buying has changed shape since April. What was a wrecked post-crash recovery trade is now a funded, pivotal-bound pan-RAS story: on 2026-07-13 Erasca published updated AURORAS-1 Phase 1 data for ERAS-0015 and laid out registration-enabling plans, and on 2026-07-14 it priced an upsized offering of 31,428,572 shares at $17.50 (~$550M gross) — equity sold one day after the data.
• The updated numbers were credible but narrow: 57% unconfirmed ORR at the 32 mg recommended dose in 2L+ KRAS G12X pancreatic cancer (n=7), median relative dose intensity 100% at both 24 mg and 32 mg, 6 of 7 patients at 32 mg and 6 of 8 at 24 mg still on treatment, no DLTs at the monotherapy recommended doses and no discontinuations attributed to treatment-related adverse events (2026-07-13 release).
• The problem is the calendar. The 2026-07-13 plan puts the registration-enabling 2L+ NSCLC trial in H1 2027, a Phase 3 in 1L pancreatic in 2027, a Phase 3 in RAS-mutant NSCLC in H2 2027–H1 2028, and the next monotherapy/combination data cut in H1 2027. Between now and then the dated events are legal and financial, not clinical.
• Life-cycle: MATURING, late in that phase. Attention expanded and was monetised (2026-07-13/14), sell-side re-marked to neutral stances with targets that bracket the tape (BofA Neutral $18 on 2026-07-14; Morgan Stanley Equal-Weight $21 on 2026-07-20), and the last dated company news is three weeks old. Price closed $18.41 on 2026-08-07, 18.1% under the $22.47 52-week high, RSI(14) 46.3 — working, not extending.

Bullish and bearish views on Erasca, Inc.

The model's bull view on Erasca, Inc. (ERAS), in brief: (data) The 2026-07-13 cut added patients and follow-up to the April dataset and held up on the dimension that usually breaks early pan-RAS assets: tolerability. The bear view: (issuance into strength) The company announced a $500M offering on 2026-07-13 and priced it upsized at $17.50 the next day. Both cases follow in full.

Bull Case

• (data) The 2026-07-13 cut added patients and follow-up to the April dataset and held up on the dimension that usually breaks early pan-RAS assets: tolerability. Median relative dose intensity 100% at 24 mg and 32 mg, low interruption/reduction rates, no treatment-related discontinuations. Dose intensity at 100% in a pancreatic population is the datapoint that makes combination and 1L ambitions plausible.
• (data) April's efficacy anchor stands: 62% unconfirmed ORR in 2L+ KRAS G12X NSCLC and 75% in post-ICI/platinum patients (2026-04-27), which is what put the asset into the same conversation as Revolution Medicines' RMC-6236.
• (combination) ERAS-0015 16 mg with panitumumab in metastatic colorectal cancer cleared its cohort with no DLTs in 4 evaluable patients, escalation ongoing at 24 mg (2026-07-13) — a second indication path that does not depend on monotherapy depth.
• (balance sheet) Cash, equivalents and marketable securities were $408.5M at 2026-03-31 versus $341.8M at 2025-12-31, with runway then guided into H2 2028 (Q1 2026 results, 2026-05-12). The July raise of ~$550M gross is additive to that base and lands before, not during, the Phase 3 spend.
• (sell-side direction) Targets moved up twice post-data: BofA to $18 (2026-07-14), Morgan Stanley to $21 (2026-07-20). Both raises came from firms holding non-buy ratings, so the move was to valuation, not to conviction.

Bear Case

• (issuance into strength) The company announced a $500M offering on 2026-07-13 and priced it upsized at $17.50 the next day. Roughly 31.4M new shares were placed at a price the stock is now only modestly above. That deal price is the reference the tape is trading against, and the 52-week high of $22.47 sits 18.1% above the 2026-08-07 close.
• (legal, unresolved) The Revolution Medicines allegation disclosed in the 2026-04-27 8-K — infringement of U.S. Patent No. 12,409,225 plus trade-secret claims tied to preclinical comparisons against RMC-6236 — has no adjudication date attached in any public reporting reviewed. Shares closed $19.50 on 2026-04-27, down 10.71%, on that disclosure, before the far larger next-session decline.
• (legal, ongoing) The securities class action in S.D. Cal. Covers a 2025-01-14 to 2026-04-26 class period with a lead-plaintiff deadline of 2026-08-10. Plaintiff-firm notices dated 2026-07-30, 2026-08-06 and 2026-08-07 are what most of the recent headline flow consists of.
• (safety history) The April dataset included a treatment-related Grade-5 pneumonitis event (66-year-old pancreatic patient, 24 mg) disclosed on the 2026-04-27 call rather than in the press release. The 2026-07-13 release reported no new Grade-5 or pneumonitis events; that is an absence in a press release, not an updated full safety table.
• (vacuum) With the next data cut guided to H1 2027, there is no company-controlled clinical catalyst to re-rate against for roughly two quarters. Multiple compression in that window happens without any thesis element being disproved.

Setup & Price Structure

• 2026-08-07 close $18.41. 52-week high $22.47; distance from high −18.1%. Three-month return +81.9%, which measures the recovery off the early-May trough, not the post-offering tape. RSI(14) 46.3 — mid-range, no momentum extension and no oversold condition.
• $17.50 is the structural line: the 2026-07-14 deal price, where roughly 31.4M shares were placed. Trade above it and the deal book is whole; sustained trade below it and the most recent large marginal buyer is offside.
• $16.01 (2026-06-26 close) is the shelf the June recovery built before the July data and financing. It is the level below which the July re-rate is fully surrendered.
• Crowding/positioning observables, stated plainly: equity issued into strength one day after positive data; both named post-data ratings are non-buy with targets of $18 and $21 straddling the close; headline flow since 2026-07-20 has been litigation-firm shareholder notices rather than company news; no insider transaction data appears in the material reviewed, so nothing is claimed either way there.

Catalyst Calendar (next 30 days)

• 2026-08-10 — Lead-plaintiff application deadline, securities class action, S.D. Cal. (class period 2025-01-14 to 2026-04-26). Sets who controls the case and starts the clock on a consolidated amended complaint.
• ~2026-08-13 (est., unconfirmed) — Q2 2026 business update and financial results. Q1 2026 was reported 2026-05-12 and Q2 2025 on 2025-08-12; an early-August earnings-preview piece flagged the print as imminent, so this window may already have opened. The checkable item whenever it lands is the post-offering cash balance and whether runway guidance is restated beyond "into H2 2028."

Elapsed catalysts

• Undated, H2 2026 — ERAS-4001 (BOREALIS-1) pan-KRAS Phase 1 monotherapy data, guided in the 2026-01-12 milestones release. The 2026-07-13 update covered ERAS-0015 only and restated no ERAS-4001 timing. This is the IP-independent readout, and it remains without a date. (passed 27d ago)
• Beyond 30 days — registration-enabling 2L+ NSCLC trial initiation H1 2027; Phase 3 1L pancreatic 2027; Phase 3 RAS-mutant NSCLC H2 2027–H1 2028; next monotherapy/combination data H1 2027 (all 2026-07-13). (passed 27d ago)

What Would Change Our Mind

• The structure that breaks first is the July financing shelf. Losing $17.50 on a sustained basis says the ~31.4M shares placed on 2026-07-14 are underwater and the data-plus-capital reset did not hold; a weekly close below $16 completes that break by giving back the 2026-06-26 recovery shelf as well, with no dated clinical catalyst before H1 2027 to lean on.
• On the fundamental side, a filed Revolution Medicines complaint or a preliminary-injunction motion naming ERAS-0015 converts an open-ended letter into a dated legal proceeding against the only asset that matters — that changes the read regardless of price.
• Upside change of mind: a dated ERAS-4001 BOREALIS-1 readout announced with a specific window, or a Q2/Q3 disclosure pulling the next ERAS-0015 data cut forward from H1 2027, would restore a company-controlled catalyst and re-open the case for the tape above $17.50.
• If the 2026-08-10 deadline passes and the consolidated complaint adds offering-related claims tied to the July deal, the litigation overhang widens from backward-looking disclosure claims to the capital raise itself.

Correlation Notes

• Closest read-across is Revolution Medicines (RVMD): simultaneously the pan-RAS category comparator and the party asserting U.S. Patent 12,409,225. RVMD clinical or legal headlines move ERAS in both directions, and a strong RVMD dataset is a competitive negative and a category positive at once.
• Second-order pathway comparables are the KRAS G12C franchises at Amgen and Bristol Myers Squibb, which set the commercial ceiling assumption for RAS-mutant NSCLC and pancreatic.
• As a pre-revenue, ~$5B-scale clinical biotech with no product cash flow, the name carries small-cap biotech beta (XBI) and rate sensitivity; the July financing was executed into an open window, and follow-on supply conditions for the sector are a live input to any further raise.
• Litigation-driven headline flow is idiosyncratic and uncorrelated to sector tape — the shareholder-notice releases dated 2026-07-30 through 2026-08-07 generate volume without any change in underlying clinical facts.